FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2317731611> ?p ?o ?g. }

• W2317731611 endingPage "495" @default.
• W2317731611 startingPage "490" @default.
• W2317731611 abstract "Overexpression of vascular endothelial growth factor in renal cell carcinoma (RCC) leads to angiogenesis, tumor progression, and inhibition of immune function. We conducted the first phase II study to estimate the efficacy and safety of bevacizumab with high-dose interleukin-2 (IL-2) therapy in patients with metastatic RCC. Eligible patients had predominantly clear cell metastatic RCC, measurable disease, a Karnofsky Performance Status of ≥80%, and adequate end-organ function. IL-2 (600,000 IU/kg) was infused intravenously every 8 hours (maximum 28 doses) during two 5-day cycles on days 1 and 15 of each 84-day course. Bevacizumab (10 mg/kg) was infused intravenously every 2 weeks beginning 2 weeks before initiating IL-2. Fifty of 51 eligible patients from 8 centers were enrolled. Median progression-free survival (PFS) was 11.2 months (90% confidence interval, 5.7-17.7), and 2-year PFS was 18% (90% confidence interval, 8%-27%). Responses included 4 complete (8%) and 11 partial (22%) responses. Toxicities did not exceed those expected from each agent alone. Combining IL-2 plus bevacizumab is feasible, with a response rate and PFS at least as high as reported previously for the single agents. The regimen did not appear to enhance the rate of durable major responses over that of IL-2 alone." @default.
• W2317731611 created "2016-06-24" @default.
• W2317731611 creator A5007052233 @default.
• W2317731611 creator A5017334876 @default.
• W2317731611 creator A5025100380 @default.
• W2317731611 creator A5029588412 @default.
• W2317731611 creator A5033346506 @default.
• W2317731611 creator A5034792001 @default.
• W2317731611 creator A5043100004 @default.
• W2317731611 creator A5043208583 @default.
• W2317731611 creator A5049243227 @default.
• W2317731611 creator A5052526230 @default.
• W2317731611 creator A5073593424 @default.
• W2317731611 creator A5075376684 @default.
• W2317731611 creator A5075566772 @default.
• W2317731611 creator A5079825829 @default.
• W2317731611 creator A5087012860 @default.
• W2317731611 creator A5089516753 @default.
• W2317731611 date "2013-11-01" @default.
• W2317731611 modified "2023-09-26" @default.
• W2317731611 title "A Phase II Study of Bevacizumab and High-dose Interleukin-2 in Patients With Metastatic Renal Cell Carcinoma" @default.
• W2317731611 doi "https://doi.org/10.1097/cji.0000000000000003" @default.
• W2317731611 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24145360" @default.
• W2317731611 hasPublicationYear "2013" @default.
• W2317731611 type Work @default.
• W2317731611 sameAs 2317731611 @default.
• W2317731611 citedByCount "23" @default.
• W2317731611 countsByYear W23177316112014 @default.
• W2317731611 countsByYear W23177316112015 @default.
• W2317731611 countsByYear W23177316112016 @default.
• W2317731611 countsByYear W23177316112017 @default.
• W2317731611 countsByYear W23177316112018 @default.
• W2317731611 countsByYear W23177316112020 @default.
• W2317731611 countsByYear W23177316112022 @default.
• W2317731611 crossrefType "journal-article" @default.
• W2317731611 hasAuthorship W2317731611A5007052233 @default.
• W2317731611 hasAuthorship W2317731611A5017334876 @default.
• W2317731611 hasAuthorship W2317731611A5025100380 @default.
• W2317731611 hasAuthorship W2317731611A5029588412 @default.
• W2317731611 hasAuthorship W2317731611A5033346506 @default.
• W2317731611 hasAuthorship W2317731611A5034792001 @default.
• W2317731611 hasAuthorship W2317731611A5043100004 @default.
• W2317731611 hasAuthorship W2317731611A5043208583 @default.
• W2317731611 hasAuthorship W2317731611A5049243227 @default.
• W2317731611 hasAuthorship W2317731611A5052526230 @default.
• W2317731611 hasAuthorship W2317731611A5073593424 @default.
• W2317731611 hasAuthorship W2317731611A5075376684 @default.
• W2317731611 hasAuthorship W2317731611A5075566772 @default.
• W2317731611 hasAuthorship W2317731611A5079825829 @default.
• W2317731611 hasAuthorship W2317731611A5087012860 @default.
• W2317731611 hasAuthorship W2317731611A5089516753 @default.
• W2317731611 hasConcept C126322002 @default.
• W2317731611 hasConcept C126894567 @default.
• W2317731611 hasConcept C141071460 @default.
• W2317731611 hasConcept C143998085 @default.
• W2317731611 hasConcept C159641895 @default.
• W2317731611 hasConcept C2776694085 @default.
• W2317731611 hasConcept C2777472916 @default.
• W2317731611 hasConcept C2777802072 @default.
• W2317731611 hasConcept C2780739268 @default.
• W2317731611 hasConcept C2781413609 @default.
• W2317731611 hasConcept C31760486 @default.
• W2317731611 hasConcept C44249647 @default.
• W2317731611 hasConcept C71924100 @default.
• W2317731611 hasConcept C90924648 @default.
• W2317731611 hasConceptScore W2317731611C126322002 @default.
• W2317731611 hasConceptScore W2317731611C126894567 @default.
• W2317731611 hasConceptScore W2317731611C141071460 @default.
• W2317731611 hasConceptScore W2317731611C143998085 @default.
• W2317731611 hasConceptScore W2317731611C159641895 @default.
• W2317731611 hasConceptScore W2317731611C2776694085 @default.
• W2317731611 hasConceptScore W2317731611C2777472916 @default.
• W2317731611 hasConceptScore W2317731611C2777802072 @default.
• W2317731611 hasConceptScore W2317731611C2780739268 @default.
• W2317731611 hasConceptScore W2317731611C2781413609 @default.
• W2317731611 hasConceptScore W2317731611C31760486 @default.
• W2317731611 hasConceptScore W2317731611C44249647 @default.
• W2317731611 hasConceptScore W2317731611C71924100 @default.
• W2317731611 hasConceptScore W2317731611C90924648 @default.
• W2317731611 hasIssue "9" @default.
• W2317731611 hasLocation W23177316111 @default.
• W2317731611 hasLocation W23177316112 @default.
• W2317731611 hasOpenAccess W2317731611 @default.
• W2317731611 hasPrimaryLocation W23177316111 @default.
• W2317731611 hasRelatedWork W1480235848 @default.
• W2317731611 hasRelatedWork W1993594227 @default.
• W2317731611 hasRelatedWork W2037221770 @default.
• W2317731611 hasRelatedWork W2080607747 @default.
• W2317731611 hasRelatedWork W2101986864 @default.
• W2317731611 hasRelatedWork W2269916035 @default.
• W2317731611 hasRelatedWork W2317731611 @default.
• W2317731611 hasRelatedWork W2325657449 @default.
• W2317731611 hasRelatedWork W2589765552 @default.
• W2317731611 hasRelatedWork W3088178260 @default.
• W2317731611 hasVolume "36" @default.
• W2317731611 isParatext "false" @default.
• W2317731611 isRetracted "false" @default.
• W2317731611 magId "2317731611" @default.

• next